摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(氨基甲基)-3-吡啶羧酸乙酯盐酸盐 | 697739-11-0

中文名称
2-(氨基甲基)-3-吡啶羧酸乙酯盐酸盐
中文别名
——
英文名称
ethyl 2-(aminomethyl)-3-pyridinecarboxylate hydrochloride
英文别名
[3-ethoxycarbonylpyridin-2-yl]methanaminium chloride;(3-Ethoxycarbonylpyridin-2-yl)methylazanium;chloride;(3-ethoxycarbonylpyridin-2-yl)methylazanium;chloride
2-(氨基甲基)-3-吡啶羧酸乙酯盐酸盐化学式
CAS
697739-11-0
化学式
C9H12N2O2*ClH
mdl
——
分子量
216.667
InChiKey
FUCIAZKOKQBGQL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.14
  • 重原子数:
    14
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    65.2
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    2-(氨基甲基)-3-吡啶羧酸乙酯盐酸盐 在 lithium aluminium tetrahydride 、 氯化亚砜乙酸酐 作用下, 以 四氢呋喃氯仿 为溶剂, 反应 21.0h, 生成 8-(chloromethyl)imidazo[1,5-a]pyridine
    参考文献:
    名称:
    SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
    摘要:
    提供了替代杂环芳醛及其衍生物,其作为血红蛋白的变构调节剂,以及其制备的方法和中间体,包括这些调节剂的药物组合物,以及在治疗由血红蛋白介导的疾病和需要增加组织氧合的疾病中使用它们的方法。
    公开号:
    US20150344483A1
  • 作为产物:
    描述:
    烟酸乙酯盐酸 、 palladium 10% on activated carbon 、 氢气间氯过氧苯甲酸二甲氨基甲酰氯 作用下, 以 乙醇二氯甲烷 为溶剂, 反应 60.0h, 生成 2-(氨基甲基)-3-吡啶羧酸乙酯盐酸盐
    参考文献:
    名称:
    [EN] SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
    [FR] COMPOSÉS BENZALDÉHYDE SUBSTITUÉS ET PROCÉDÉS D'UTILISATION DE CEUX-CI DANS L'AUGMENTATION DE L'OXYGÉNATION DES TISSUS
    摘要:
    提供了替代苯甲醛及其衍生物,其作为血红蛋白的变构调节剂,以及其制备的方法和中间体,包括这些调节剂的药物组合物,以及在治疗由血红蛋白介导的疾病和需要增加组织氧合的疾病中使用它们的方法。
    公开号:
    WO2013102142A1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION<br/>[FR] COMPOSÉS D'ALDÉHYDES HÉTÉROARYLES SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION DANS L'ACCROISSEMENT DE L'OXYGÉNATION TISSULAIRE
    申请人:GLOBAL BLOOD THERAPEUTICS INC
    公开号:WO2013102145A1
    公开(公告)日:2013-07-04
    Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    提供了替代杂环芳醛及其衍生物,其作为血红蛋白的变构调节剂,以及其制备的方法和中间体,包括这些调节剂的药物组合物,以及在治疗由血红蛋白介导的疾病和需要增加组织氧合的疾病中使用它们的方法。
  • [EN] AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN<br/>[FR] HETEROCYCLES AMINES EN TANT QU'ANTAGONISTES DU RECEPTEUR VANILLOIDE (VR-1) POUR LE TRAITEMENT DE LA DOULEUR
    申请人:MERCK SHARP & DOHME
    公开号:WO2004046133A1
    公开(公告)日:2004-06-03
    the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C-Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C-Ar2, with the proviso that when Y is N or CH then Z is C-Ar2, and with the further proviso that when Y is C-Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CONR3R4, NR3SO2R6, SO2NR3R4, -(CH2)mcarboxy, esterified -(CH2)mcarboxy or -(CH2)mNR3R4; R2 represents hydrogen, halogen, hydroxy, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, haloC1-6alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; R3 and R4 are each independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl or fluoroC1-6alkyl; or R3 and R4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C1-4alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O)2, or NR5; R5 represents hydrogen, C1-4alkyl, hydroxyC1-4alkyl or C1-4alkoxyC1-4alkyl; R6 represents hydrogen, C1-6alkyl, fluoroC1-6alkyl, C3-7cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.
    本发明提供了一种具有以下结构的化合物(I):其中V代表NR5、O、S、SO或S(O)2;W和X分别独立地代表CH或N;Y代表N、CH或C-Ar2,但至少有一个但不超过两个W、X和Y为N;Z代表CH或C-Ar2,但当Y为N或CH时,则Z为C-Ar2,并进一步规定当Y为C-Ar2时,Z为CH;Ar1代表包含一个、两个、三个或四个从氮、氧和中选择的杂原子的融合的9或10成员杂双环系统,其中所述环系中的至少一个环是芳香的;Ar2代表选择自苯基、吡啶基、嘧啶基和吡啶嗪基的芳香环,可以是可选地融合和取代的;R1代表卤素、羟基、氧、C1-6烷基、C2-6烯基、C2-6炔基、卤代C1-6烷基、羟基C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、羟基C1-6烷氧基、C3-7环烷基、C3-7环烷氧基、C3-5环烷基C1-4烷基、基、硝基、SR6、SOR6、SO2R6、COR6、NR3COR6、CONR3R4、NR3SO2R6、SO2NR3R4、-(CH2)m羧基、酯化的-( )m羧基或-( )mNR3R4;R2代表氢、卤素、羟基、C1-6烷基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基、卤代C1-6烷氧基、未取代的苯基或苯基,其上取代有一个或两个从卤素、C1-6烷基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基或卤代C1-6烷氧基中选择的基团;R3和R4各自独立地代表氢、C1-6烷基、C2-6烯基、C2-6炔基、C3-7环烷基或代C1-6烷基;或R3和R4和它们连接的氮原子共同形成一个由4到7个环原子组成的杂原烷环,可选地取代为一个或两个从羟基或C1-4烷氧基中选择的基团,该环可能可选地包含作为所述环原子之一的氧或原子、S(O)、S(O)2或NR5;R5代表氢、C1-4烷基、羟基C1-4烷基或C1-4烷氧基C1-4烷基;R6代表氢、C1-6烷基、代C1-6烷基、C3-7环烷基、未取代的苯基或苯基,其上取代有一个或两个从卤素、C1-6烷基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基或卤代C1-6烷氧基中选择的基团;m为零或从1到4的整数;n为零或从1到3的整数;或其药学上可接受的盐、N-氧化物或前药;包含它的药物组合物;其在治疗方法中的用途;用于制造用于治疗VR-1相关病症的药物,例如疼痛和/或炎症占优势的病症的用途;以及使用它的治疗方法。
  • Amino-heterocycles as vr-1 antagonists for treating pain
    申请人:Blurton Peter
    公开号:US20060040947A1
    公开(公告)日:2006-02-23
    the present invention provides a compound of formula (I): wherein V represents NR 5 , O, S, SO or S(O) 2 ; W and X each independently represent CH or N; Y represents N, CH or C—Ar 2 , with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C—Ar 2 , with the proviso that when Y is N or CH then Z is C—Ar 2 , and with the further proviso that when Y is C—Ar 2 then Z is CH; Ar 1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar 2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R 1 represents halogen, hydroxy, oxo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, haloC 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, hydroxyC 1-6 alkoxy, C 3-7 cycloalkyl, C 3-7 cycloalkoxy, C 3-5 cycloalkylC 1-4 alkyl, cyano, nitro, SR 6 , SOR 6 , SO 2 R 6 , COR 6 , NR 3 COR 6 , CONR 3 R 4 , NR 3 SO 2 R 6 , SO 2 NR 3 R 4 , —(CH 2 ) m carboxy, esterified —(CH 2 ) m carboxy or —(CH 2 ) m NR 3 R 4 ; R 2 represents hydrogen, halogen, hydroxy, C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy or haloC 1-6 alkoxy; R 3 and R 4 are each independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl or fluoroC 1-6 alkyl; or R 3 and R 4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C 1-4 alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O) 2 , or NR 5 ; R 5 represents hydrogen, C 1-4 alkyl, hydroxyC 1-4 alkyl or C 1-4 alkoxyC 1-4 alkyl; R 6 represents hydrogen, C 1-6 alkyl, fluoroC 1-6 alkyl, C 3-7 cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy or haloC 1-6 alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.
    本发明提供了一种化合物,其化学式为(I):其中V代表NR5、O、S、SO或S(O)2;W和X各自独立地代表CH或N;Y代表N、CH或C-Ar2,但至少有一个,但不超过两个,W、X和Y是N;Z代表CH或C-Ar2,但当Y为N或CH时,Z为C-Ar2,且进一步规定当Y为C-Ar2时,Z为CH;Ar1代表一个融合的9或10个成员的杂双环环系统,其中包含从氮、氧和中选择的一个、两个、三个或四个杂原子,其中至少一个环为芳香环;Ar2代表一种芳香环,选择自苯基、吡啶基、嘧啶基和吡啶嗪基,可选地融合和取代;R1代表卤素、羟基、氧代、C1-6烷基、C2-6烯基、C2-6炔基、卤代C1-6烷基、羟基C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、羟基C1-6烷氧基、C3-7环烷基、C3-7环烷氧基、C3-5环烷基C1-4烷基、基、硝基、SR6、SOR6、SO2R6、COR6、NR3COR6、CONR3R4、NR3SO2R6、SO2NR3R4、-(CH2)m羧基、酯化的-( )m羧基或-( )mNR3R4;R2代表氢、卤素、羟基、C1-6烷基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基、卤代C1-6烷氧基、未取代苯基或取代一个或两个群的苯基,所述群从卤素、C1-6烷基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基或卤代C1-6烷氧基中选择;R3和R4各自独立地代表氢、C1-6烷基、C2-6烯基、C2-6炔基、C3-7环烷基或代C1-6烷基;或R3和R4及它们所连接的氮原子一起形成4至7个环原子的杂脂环,可选地取代一个或两个群,所述群从羟基或C1-4烷氧基中选择,该环可以选择地包含一个氧原子或原子、S(O)、S(O)2或NR5作为其中一个所述环原子;R5代表氢、C1-4烷基、羟基C1-4烷基或C1-4烷氧基C1-4烷基;R6代表氢、C1-6烷基、代C1-6烷基、C3-7环烷基、未取代苯基或取代一个或两个群的苯基,所述群从卤素、C1-6烷基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基或卤代C1-6烷氧基中选择;m为零或1至4的整数;n为零或1至3的整数;或其药学上可接受的盐、N-氧化物或前药;包含它的制药组合物;它在治疗方法中的用途;用于制造治疗VR-1相关疾病的药物,例如疼痛和/或炎症占主导地位的疾病;以及使用它的治疗方法。
  • SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
    申请人:Global Blood Therapeutics, Inc.
    公开号:US20130190315A1
    公开(公告)日:2013-07-25
    Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    提供一种替代苯甲醛及其衍生物,其作为血红蛋白的异构调节剂,以及其制备的方法和中间体,包括该调节剂的制药组合物,以及使用该组合物治疗由血红蛋白介导的疾病和需要增加组织氧合的疾病的方法。
  • Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
    申请人:Global Blood Therapeutics, Inc.
    公开号:US09012450B2
    公开(公告)日:2015-04-21
    Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    提供了替代杂环芳香醛及其衍生物,可作为血红蛋白的异构调节剂,其制备方法和中间体,包含这些调节剂的药物组成物,以及用于治疗由血红蛋白介导的疾病和需要增加组织氧合的疾病的方法。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-